Phase Ib Study of XMT-1660 in Solid Tumors Likely to Express B7-H4

Cancer
Ritesh Parajuli
A Phase Ib, First-In-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors
Anus
Bones and Joints
Brain and Nervous System
Breast
Cervix
Colon
Corpus Uteri
Esophagus
Eye and Orbit
Ill-Defined Sites
Kidney
Larynx
Lip Oral Cavity and Pharynx
Liver
Lung
Melanoma skin
Other Digestive Organ
Other Endocrine System
Other Female Genital
Other Male Genital
Other Respiratory and Intrathoracic Organs
Other Skin
Other Urinary
Ovary
Pancreas
Prostate
Rectum
Small Intestine
Soft Tissue
Stomach
Thyroid
Unknown Sites
Urinary Bladder

Study Description

A Study of XMT-1660 in Solid Tumors

Eligibility

-Participants must be at least 18 years of age

-Participant has proven recurrent or advanced solid tumor and has disease progression

after treatment with available anti-cancer therapies known to confer benefit or is

intolerant to treatment

-Participant must be willing to undergo a minimally invasive tumor biopsy to obtain tumor

tissue for local testing, if medically feasible, prior to C1D1.

-Participant has received prior treatment with another ADC containing an auristatin or

maytansinoid payload (e.g., mirvetuxuximab)

-Major surgery within 28 days of starting study treatment, systemic anticancer therapy within the time period of 28 days or 5 half-lives of the prior therapy before starting study treatment (14 days or 5 half-lives for small molecule targeted therapy), whichever is less, or palliative radiation therapy within 14 days of starting study treatment.

-Participants with human immunodeficiency virus (HIV) infection are excluded from

study entry. An HIV test is required during Screening

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.